David Hennings

Dr. David Hennings is the Vice President of CMC for Sudo Biosciences. Prior to Sudo, he was Vice President of CMC for Cortexyme, a pharmaceutical company developing novel treatments for neurodegenerative diseases, where he was responsible for the development and delivery of drug substance and drug product to support the company’s lead candidate in clinical trials. Dr. Hennings served in positions of increasing responsibility over a 14-year tenure at Array Biopharma (acquired by Pfizer), where he established interdisciplinary CMC teams to manage the development of multiple programs in oncology as well as other therapeutic areas such as antibacterial products and pain/inflammation in oncology.